Atai Life Sciences N.V. (ATAI)

2.0500 -0.0800 (-3.76%) 收市：04:00PM EDT

Atai Life Sciences N.V.

Wallstrasse 16
Berlin 10179
Germany
49 89 2153 9035
https://www.atai.life

版塊: Healthcare
行業: Biotechnology
全職員工: 83

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Christian Angermayer	Founder & Chairman of the Supervisory Board	70k	無	1978
Mr. Florian Brand	Co-Founder, MD & CEO	793.33k	無	1987
Dr. Srinivas G. Rao M.D., Ph.D.	Co-Founder & Chief Scientific Officer	793.65k	無	1969
Ms. Anne Johnson	Chief Financial Officer	494.23k	無	1969
Dr. Michael Raven Ph.D.	Senior Vice President of Operations	無	無	無
Mr. Frank Stegert	Vice President of Investment & Venture Management	無	無	1981
Mr. Ryan Barrett	Senior VP, General Counsel & Corporate Secretary	無	無	1981
Dr. Glenn Short Ph.D.	Senior Vice President of Early Development	無	無	無
Dr. Sahil V. Kirpekar M.D.	Chief Business Officer	無	無	1986
Dr. Kevin Craig M.D.	Senior Vice President of Clinical Development	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

公司管治

截至 無 止，Atai Life Sciences N.V. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。